This Program Project focuses on elucidating the role and actions of novel specialized pro-resolving mediators (SPM) in inflammation and acute tissue injury. In service to this Program Project to achieve its goals, this Core, SPM-Lipidomics and Metabolomics, will provide centralized, standardized and coordinated lipid mediator (LM) lipidomic profiling methods and procedures for Projects 1-4 and Core C. Core B will execute newly established procedures and methods for SPM lipidomics and LM pathway metabolomics as a central service that will be required routinely by Projects 1-4 and Core C. This core will also develop, validate and implement new lipidomic approaches when needed. By providing a centralized location for the LM lipidomics and pathway metabolomics as standardized services, Core B eliminates costly duplication of instruments and personnel within each project. In addition, Core B will characterize the physical properties of synthetic compounds prepared by total organic synthesis in Project 4, and will match these for validation to biologically generated novel SPM, including resolvins, protectins and maresins, before distributing the main bioactive synthetic SPM to each project and Core C for assessing their functional roles. Prioritization of the services and selection of the specific procedures will be determined through individual meetings with project and core investigators at periodic Program Project group meetings to achieve the optimal use of resources and experience of this Core in a cost-effective and timely fashion for the investigators in this Program Project.
Core B will serve Projects 1-4 and play a key role in optimizing resources and standardizing methods for identifying, validating and profiling LM in acute inflammation, tissue injury, and their resolution. By providing these centralized services, Core B will facilitate interactions and coordinate key experiments for the investigators in this Program Project.
|Sulciner, Megan L; Serhan, Charles N; Gilligan, Molly M et al. (2018) Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med 215:115-140|
|Loynes, Catherine A; Lee, Jou A; Robertson, Anne L et al. (2018) PGE2 production at sites of tissue injury promotes an anti-inflammatory neutrophil phenotype and determines the outcome of inflammation resolution in vivo. Sci Adv 4:eaar8320|
|Zhang, Linlin; Terrando, Niccolò; Xu, Zhen-Zhong et al. (2018) Distinct Analgesic Actions of DHA and DHA-Derived Specialized Pro-Resolving Mediators on Post-operative Pain After Bone Fracture in Mice. Front Pharmacol 9:412|
|Dalli, Jesmond; Serhan, Charles N (2018) Immunoresolvents signaling molecules at intersection between the brain and immune system. Curr Opin Immunol 50:48-54|
|Norris, Paul C; Serhan, Charles N (2018) Metabololipidomic profiling of functional immunoresolvent clusters and eicosanoids in mammalian tissues. Biochem Biophys Res Commun 504:553-561|
|Werz, Oliver; Gerstmeier, Jana; Libreros, Stephania et al. (2018) Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun 9:59|
|Colas, Romain A; Ashton, Anthony W; Mukherjee, Shankar et al. (2018) Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. Infect Immun 86:|
|Sham, Ho Pan; Walker, Katherine H; Abdulnour, Raja-Elie E et al. (2018) 15-epi-Lipoxin A4, Resolvin D2, and Resolvin D3 Induce NF-?B Regulators in Bacterial Pneumonia. J Immunol 200:2757-2766|
|Abdulnour, Raja-Elie E; Howrylak, Judie A; Tavares, Alexander H et al. (2018) Phospholipase D isoforms differentially regulate leukocyte responses to acute lung injury. J Leukoc Biol 103:919-932|
|Halade, Ganesh V; Kain, Vasundhara; Serhan, Charles N (2018) Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure. FASEB J 32:3717-3729|
Showing the most recent 10 out of 165 publications